HLS Therapeutics Inc. announced that it has entered into a Product Listing Agreement ("PLA") with Ontario, for the listing and public reimbursement of Vascepa (icosapent ethyl) on the province's Public Prescription Drug Insurance Plan. The PLA with Ontario is effective July 21, 2022. Under the terms of the PLA, Vascepa will be reimbursed for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with
established cardiovascular disease and elevated triglycerides.